Compare Marathon Petroleum Corp (MPC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs Recursion Pharmaceuticals Inc — how do they compare? Marathon Petroleum Corp trades at $468.5 (market cap $130.12B), while Recursion Pharmaceuticals Inc trades at $4.17 (market cap $2.14B). The key difference: Marathon Petroleum Corp is far larger — about 60.8× Recursion Pharmaceuticals Inc's market cap, and Marathon Petroleum Corp pays a 0.86% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marathon Petroleum Corp for 54 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| MPC | RXRX | |
|---|---|---|
Market Cap | $130.12B | $2.14B |
Volume | 2,749,647 | 30,789,535 |
Sector | Energy | Health |
52-Week High | $463.34 | $6.79 |
52-Week Low | $162.63 | $2.84 |
Typical Hold Time | 54 Days | 22 Days |
Enterprise Value | $156.64B | $1.66B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $442.26, up 2.29% today, reflecting strong momentum amid bullish technical signals and recent earnings beats. The stock shows robust profitability with a 47.9% ROE and trades at a P/E of 16.07, below the sector average. Recent news highlights refining margin strength and positive analyst sentiment, though risks include potential diesel export restrictions and volatile energy markets.
Outlook remains positive with 75.8% of analysts rating it a buy and a consensus price target of $420.30. Key opportunities include elevated refining margins and solid cash flow, while risks involve regulatory uncertainty and cyclical demand pressures. The stock's valuation and growth prospects support a constructive view for investors seeking energy exposure.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
